Welcome back, Ard. We've noticed quite an influx lately. How's it feel to be part of an influx? <g>
This site (and our sister site, Investors Hub) get an influx this time every year. The January Effect surely being part of the reason. But this time it's different. It's BIG. Plus, I'm taking the unprecedented step of actually marketing the site. That's never been done in the history of either site, save for a banner exchange in which iHub used to participate. It seems we could very well finally be starting to round that corner I've been waiting nearly 3 years to get to.
And hopefully some of it is helped by Dave and I actually participating in stock discussions. That was verboten previously. Now that we're owners of the place (did you hear about that in your absence?), we don't impose such a rule on ourselves. Dave, Matt, and I are investors/traders or we wouldn't be interested in this line of work, so it's perfectly reasonable for us to want to participate.
That said, is ELN a Gorilla yet? Obscene gains in a relatively short time from $3 to what looks like a $16 open today. And, IMO, though some of these gains are because it's widely believed that Tysabri will be back on the market or at least advanced clinical trials in about 2 months, I think another reasons (and what's motivated me to invest heavily in it) is that it's slowly being realized that the company isn't a one-trick pony. There's AAB-001 (which has shown in early trials to not only slow down the progress of Alzheimers, but to actually often REVERSE the damage), and there's NanoCrystal technology which is starting to get licensed by other pharmas, often to put life back into drugs that had to be shelved. The company hasn't given us anything we can use to quantify the value of its NanoCrystal technology, and to my knowledge nothing has met FDA approval yet using it, but there are a few in the pipeline.
As big a blockbuster as Tysabri was expected to be (the stock was over $30 before the plug was pulled), I have this sneaking suspicion that NanoCrystal is going to prove to be the company's bread and butter.
Opinions? |
